Mobic Labeling Revision Includes Class Risk Language
This article was originally published in The Pink Sheet Daily
Executive SummaryBoehringer Ingelheim’s addition of cardiovascular and gastrointestinal risk information to Mobic labeling coincides with FDA approval of a juvenile rheumatoid arthritis indication for meloxicam.
You may also be interested in...
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.